1 / 86

Synthesis & Release of Neurotransmitters

Synthesis & Release of Neurotransmitters. Sympathetic Nervous System. Origin Transmitters Receptors Sympathomimetic drugs Sympathetic Antagonists. Noradrenergic Transmission. Classification of Adrenoceptors:  -adrenoceptors : Subtypes (  1 &  2 )

vancem
Download Presentation

Synthesis & Release of Neurotransmitters

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Synthesis & Release of Neurotransmitters

  2. Sympathetic Nervous System • Origin • Transmitters • Receptors • Sympathomimetic drugs • Sympathetic Antagonists

  3. Noradrenergic Transmission Classification of Adrenoceptors: -adrenoceptors : Subtypes ( 1&2 ) α1 causes vasoconstriction , mydriasis α2 inhibit insulin & renin release

  4. -adrenoceptors : Subtypes ( 1 , 2 & 3) β1 increases all cardiac properties ,renin & insulin release & lipolysis β2 vasodilation, relax all non vascular smooth muscles, increase liver & muscle glycogenolysis β3inhibit production of leptin

  5. Classification of Adrenoceptor Agonists A: Catecholamines: epinephrine, norepinephrine, isoproterenol & dopamine.

  6. b) inactivation by COMT MAO enzymes inactivate within other tissues as in liver & gut wall. c) Short duration of action. d) Poor penetration into the C.N.S.

  7. Classification of Adrenoceptor Agonists B: Non Catecholamines: • Lacking hydroxyl group. • Long half-life. • Given orally. • . Phenylephrine, ephedrine, amphetamine. • Penetrate better to C.N.S.

  8. Classification According to Mechanism of Action 1- Direct-acting Agonists: e.g.: Epinephrine, norepinephrine, isoproterenol, phenylephrine. 2- Indirect-acting Agonists: Taken up into the presynaptic neuron & cause the release of norepinephrine e.g. amphetamine

  9. 3- Mixed-acting Agonists: E.g.: Ephedrine

  10. Pharmacological Actions of Sympathomimetic Drugs 1- CVS: 1 (Heart): Positive inotropic &chronotropic &C.O. Increase oxygen demands on the myocardium.

  11. 2 : • Vasodilation of sketal muscles blood vessels. α1- • V.C. of blood vessels in the skin & mucous membranes leading to  in mean blood pressure.

  12. 2- Eye: 1 :  mydriasis. In open-angle glucoma decrease production of aqueous humor by vasoconstriction of the ciliary body blood vessels. .

  13. 3- Respiratory Tract: 2 : potent bronchodilator 1: causes vasoconstriction of blood vessels of the upper respiratory tract mucosa  decongestion. 4- GIT: Relaxation of GIT S.M through 2 & 2–

  14. 5- Exocrine Glands: Regulate secretion of amylase & water from salivary gland,  sweat production 6- Metabolic: • 1) β2 : • Hyperglycemia

  15.  Release of glucagon • Lipolysis - 2) 2: Decrease insulin release - 3) β3Inhibit the production of leptin by adipose tissue

  16. 7- Uterine Smooth Muscle: β2: Delay premature labour through relaxing uterine smooth muscles

  17. 8- Genitourinary system α1 :stimulate smooth muscle proliferation in various tissues. E.g.: prostate. β1: stimulate renin secretion α2 : inhibit renin secretion

  18. 9- SK.M.: β2 Improve rate & force of contraction used by sport-men to improve performance

  19. 10- C.N.S.: Indirect catecholamines have a marked stimulant effect .

  20. Specific Sympathomimetic Drugs Direct Acting: 1- Epinephrine: prototype Stimulates both 1&2 & 1&2 receptors.

  21. Pharmacokinetics - Rapid onset. - Short duration of action. - Given: I.V, S.C, endotracheal tube, inhalation, topically on eye. - Excreted in urine.

  22. Clinical uses 1- Bronchospasm. 2- Anaphylactic shock. 3- Acute asthma (S.C. ). 4- Glaucoma. 2% Topically to reduce I.O.P. in open-angle glaucoma.

  23. 5- Cardiac arrest. 6- In anaesthesia with local anaesthetic: a) Increase the duration of L.A. ( by V.C. at the site of injection ). b) Decrease the dose of L.A. c) Decrease the side effects of L.A. d) Control blood oozing of capillary blood ( Local haemostatic effect by V.C. ).

  24. Adverse Effects: 1- C.N.S.: Anxiety, fear, tension, headache, tremor. 2- Hemorrhage: Cerebral hemorrhage as a result of  B.P. 3- Cardiac arrhythmias. 4- Hyperglycemia

  25. 2- Norepinephrine: - Acts on all types of adrenergic receptors but mainly on α drenoceptors. - Increase peripheral resistance & both systolic & diastolic B.P. - Reflex bradycardia .

  26. Clinical Uses: I.V.I to treat shock

  27. 3- Isoproterenol ( Isoprenaline): Stimulates both 1 & 2. 1-Used in atrioventricular block or cardiac arrest. 2- Acute attack of asthma

  28. Adverse Effects: As epinephrine.

  29. 4- Dopamine: • Activates α &β adrenoceptors. • D1 & D2 dopaminergic receptors vasodilation

  30. Theraplutic Uses: 1- Shock (I.V.I.) increase B.P & improves blood flow to viscera. 2- Acute heart failure Adverse Effects: Hypertension, arrhythmias, angina.

  31. 5- Dobutamine: Selective 1–receptor agonist . Uses: Acute heart failure Adverse Effects:

  32. 6- Phenylephrine: - Acts primarily on  mainly 1receptors. - V.C.   both systolic & diastolic B.P. - Reflex bradycardia .

  33. Topically as nasal decongestant ( produce prolonged vasoconstriction ). Adverse Effects: Hypertensive headache, cardiac irregularities.

  34. 7- Clonidine: Is an 2 agonist, used in essential hypertension to lower BP ( action on CNS ). Used to minimize the symptoms of withdrawal from opiates or benzodiazepines .

  35. 8- Metaproterenol: - Is not a catecholamines. - Not metabolized by COMT. - Given: orally or by inhalation. - Acts on β1 &β2mainly on 2–receptors. - Used to treat asthma & bronchospasm.

  36. 9- Terbutaline: - Short acting 2 agonist. - By inhalation to treat acute asthma. - Produces less cardiac stimulation.

  37. Indirect-Acting Adrenergic Agonists 1- Amphetamine: - Acts on  &  receptors. - Marked central stimulatory action . a) Attention-deficit hyperactivity disorder of children. b) Narcolepsy(alerting effect &improved attention). c) Appetite control (suppressing effect) as in obesity d) Contraindicated in pregnancy Adverse effects : C.N.S. , Addiction.

  38. 2- Methamphetamine: Has a higher CNS effect used as anorexigenic. 3- Tyramine: Found in fermented food as cheese. With MAOI  serious vasopressor Effects causing increasing in B.P.

  39. Mixed-Acting Adrenergic Agonists 1- Ephedrine: ( a plant alkaloid ) Indirect & direct acting on  &  receptors. - Similar to epinephrine but less potent. - Not a catecholamine drug. • Long duration. • C.N.S. stimulant better than epinephrine.

  40. - Absorbed well orally. - Used as prophylactic in chronic asthma.

  41. - Enhances skeletal muscle contractility & improves motor function in myasthenia gravis. - Mild stimulation to CNS  alertness,  fatigue, insomnia. - Improves athletic performance. - Nasal decongestant. •  BP.

  42. Ephedrine (cont.) • Is useful in the treatment of stress incontinence. • Pseudoephedrine(stereoisomerofephedrine) used orally for the relief of nasal congestion. • Less potent than ephedrine in producing tachycardia, hypertension, C.N.S. stimulation. • Used in the treatment of stress incontinence.

  43. Classification of -receptor Antagonists * non-selective e.g. phenoxybenzamine & phentolamine. * 1-selective antagonists e.g. prazosin/ terazosin, doxazosin. * 2-selective antagonists e.g. yohimbine, idazoxan.

  44. Non-Selective - Adrenoceptor Antagonists Phenoxybenzamine: Blocks both 1 and 2 irreversibly . Blocks the action of histamine ,Ach & 5HT. Long-acting (24hrs).

  45. Phentolamine: Produces a competitive blocking of 1 & 2 receptors.-short acting (few hrs). Both drugs cause: 1) Postural hypotension. 2) Reflex tachycardia.

  46. - Increase in C.O. & H.R. ( reflex response to the fall in B.P, mediated through - adrenoceptors, also due to block 2 in heart ).

  47. N.B.: The block of 2–adrenoceptors increase in noradrenaline release which make the drug unsuccessful in maintaining lowered blood pressure.

  48. Therapeutic Uses: 1- Pheochromocytoma. 2- Raynaud,s disease.

  49. Adverse Effects: - Phenoxybenzamine causes postural hypotension, nasal stuffiness, nausea, vomiting, impotence, tachycardia. - Phentolamine: As phenoxybenzamine but more to induce cardiac arrhythmias and anginal pain. Both are contra-indicated in patients with decreased coronary perfusion.

  50. Selective 1- Antagonists Prazosin (short half-life) ,doxazocin& terazocin (long half life )allowing once- daily dosing. 1–antagonists cause vasodilatation & fall in arterial pressure, but less tachycardia than with non- selective blockers.

More Related